Genomic Health Announces Formation of New Genetics Subsidiary
REDWOOD CITY, Calif., Feb. 6, 2012 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced plans to establish a wholly owned subsidiary with the goal of improving the quality of diagnosis, communication and support for millions of patients and their families faced with common and rare genetic conditions. The subsidiary is expected to be established by March 1, 2012 and provide its first commercial service in 2013. The new venture will be led ...
Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice in order to improve healthcare for billions of people. There are three stages to Invitae’s business model:
Invitae Corporation’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas.
In Invitae's second quarter of 2016, the company made substantial progress on all four of its key metrics: COGS, content, volume, and reimbursement
Invitae expands its comprehensive, high-quality, affordable genetic tests
Survey shows education still needed around family health history and genetic testing
Survey on rare diseases demonstrates impact of delayed diagnosis and obstacles for patients and clinicians